Interim – Alligator Bioscience

2026-08-26

Regulatory

Alligator Bioscience AB reports financial results for the period 1 January – 30 June 2026 and provides a business update

Strategic refocus: After the quarter, Alligator discontinued all further independent development of mitazalimab and refocused on preserving ...

2026-05-05

Regulatory

Mitazalimab momentum: Final OPTIMIZE‑1 outcomes were presented at ASCO GI 2026, with additional investigator‑initiated data acce ...

2026-02-12

Regulatory

Rights issue completed: Approximately SEK 91 million (gross) raised in December, strengthening financial position with additional warrant up ...

2025-10-23

Regulatory

Upcoming rights issue of approx. SEK 120 million (gross), providing 6–9 months of financial runway during 2026, announced 22 October S ...

2025-07-10

Regulatory

GMP manufacturing completed, paediatric waiver granted, positive outcome from FDA and EMA interactions; advancing mitazalimab toward Phase 3 ...

2025-04-24

Regulatory

24-month data from OPTIMIZE-1 show 29.4% survival rate for mitazalimab—three times higher than chemotherapy alone FDA alignment secure ...

2025-01-22

Regulatory

Sharpened focus on mitazalimab and cost-reduction program to maximize long-term value creation Announcement of rights issue of units of appr ...

2024-10-24

Regulatory

Recruitment completed of 450 µg/kg back-fill cohort in the mitazalimab OPTIMIZE-1 study in pancreatic cancer Positive interim Phase 1 ...

2024-07-112024-07-11

Regulatory

Substantial overall survival benefit and unprecedented Duration of Response reported in 18-month analysis from mitazalimab OPTIMIZE-1 Phase ...